TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15515112

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 928

Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 928
Study: 11678788

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9140670

Group type: EXPERIMENTAL
Intervention: Nisoldipine (0.05 mg intracoronary during procedure, followed by 20 mg/day orally for 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nitrates (0.8 mg intracoronary during procedure, followed by 80-120 mg/day orally for 6 months)
Number of subjects: 36
Study: 7526025

Group type: EXPERIMENTAL
Intervention: Synthetic membranes used during hemodialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiologic concentrations of the platelet specific agonist ADP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complement factors C3a or C5a
Number of subjects: 0
Study: 2889217

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine twice daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: 2 mg dexchlorpheniramine maleate 3-times daily
Number of subjects: 65
Study: 2792117

Group type: EXPERIMENTAL
Intervention: Preparatory video film (14 min)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No video film (Control Group 1)
Number of subjects: 65
Study: 4686554

Group type: EXPERIMENTAL
Intervention: Inhaled aerosols of prostaglandin F(2)alpha (PGF(2)alpha)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled aerosols of histamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled aerosols of prostaglandin E(2) (PGE(2))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simultaneous inhalation of a 100-times higher PGE(2) dose with PGF(2)alpha
Number of subjects: 20
Study: 31488494

Group type: EXPERIMENTAL
Intervention: Single dose of oral azithromycin (20 mg/kg)
Number of subjects: 21712

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 21712
Study: 29657696

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 60
Study: 25798729

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 847
Study: 23559676

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard therapy (without GH)
Number of subjects: 33
Study: 21733178

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol with fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive function tests (Short Memory Orientation Memory Concentration Test and Rancho Los Amigos Scale)
Number of subjects: 0
Study: 18850309

Group type: EXPERIMENTAL
Intervention: 6% alanine (ALA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% alanine and 6% sucrose (ALA-CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 6% sucrose (CHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: artificially sweetened placebo (PLC)
Number of subjects: 10
Study: 16914701

Group type: EXPERIMENTAL
Intervention: Daptomycin (6 mg/kg daily)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard therapy (initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 246
Study: 14992900

Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin (150 to 300 U/kg bolus) with protamine reversal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study: 11382659

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg/d)
Number of subjects: 50
Study: 9427886

Group type: EXPERIMENTAL
Intervention: Obese pediatric subjects at diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anorexia nervosa patients at diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bulimia nervosa patients at diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy boys and girls at various Tanner stages
Number of subjects: 0
Study: 8489977

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous morphine alone (Control)
Number of subjects: 60
Study: 3693714

Group type: EXPERIMENTAL
Intervention: Nursing process approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 31067214

Group type: EXPERIMENTAL
Intervention: Clinical medication review (CMR)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 629
Study: 28882471

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 26133666

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ER niacin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control HDL
Number of subjects: 37
Study: 23205593

Group type: EXPERIMENTAL
Intervention: Standard Cognitive Behavioural Therapy (SCBT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behaviour Therapy (ECBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 57
Study: 21980168

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg MDMA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.6 mg/kg MDMA
Number of subjects: 10
Study: 18697901

Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation (500 microg/day phylloquinone)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (no vitamin K supplementation)
Number of subjects: 355
Study: 15972298

Group type: EXPERIMENTAL
Intervention: Azathioprine 2 mg/kg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: 5-aminosalicylic acid 3.2 g/day
Number of subjects: 72
Study: 12947422

Group type: COMPARATOR
Intervention: Ordinary caviar paste (25 g daily for 3 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fish oil enriched caviar paste (25 g daily for 3 weeks)
Number of subjects: 16
Study: 11930370

Group type: EXPERIMENTAL
Intervention: Resin-bonded bridges with grooves in abutment teeth preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resin-bonded bridges placed in the maxilla
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bonding systems (etching/Clearfil F2, sand blasting/Panavia EX, silica-coating/Microfill Pontic C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silica coating/Microfill Pontic C in rebonded bridges
Number of subjects: 0
Study: 8954425

Group type: EXPERIMENTAL
Intervention: Alginate wound dressing
Number of subjects: 92

Group type: COMPARATOR
Intervention: Dextranomer paste (Control)
Number of subjects: 92
Study: 1722576

Group type: EXPERIMENTAL
Intervention: Transabdominal CVS
Number of subjects: 2931

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Transcervical CVS
Number of subjects: 2931
Study: 6130952

Group type: EXPERIMENTAL
Intervention: 100 mg etintidine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100 mg cimetidine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 300 mg etintidine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 300 mg cimetidine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29684829

Group type: EXPERIMENTAL
Intervention: Training programme (n=81)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Waiting list control (n=65)
Number of subjects: 146
Study: 27487406

Group type: EXPERIMENTAL
Intervention: Oscillatory Biofield Therapy (OBFT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study: 24717640

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg, orally once a day for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (orally once a day for 6 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22908774

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg administered without cost for 4 months (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Solifenacin 5 mg administered with cost for 4 months (Group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg administered without cost (Group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Solifenacin 5 mg administered with cost (Group B)
Number of subjects: 70
Study: 20149716

Group type: EXPERIMENTAL
Intervention: Nelfilcon A Plus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other lenses (Hilafilcon B, Etafilcon A Plus, Nelfilcon A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All lenses
Number of subjects: 0
Study: 18333867

Group type: EXPERIMENTAL
Intervention: 300 mg oral (14)C‐labelled maraviroc
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30 mg intravenous maraviroc
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100 mg oral maraviroc
Number of subjects: 20
Study: 15819354

Group type: EXPERIMENTAL
Intervention: Test gel containing ACP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 0
Study: 12464983

Group type: EXPERIMENTAL
Intervention: Quinapril (titrated up to 40 mg daily)
Number of subjects: 2204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2204
Study: 9475259

Group type: EXPERIMENTAL
Intervention: Quinapril (QUI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Triamterene/Hydrochlorothiazide (THCT)
Number of subjects: 44
Study: 7629614

Group type: EXPERIMENTAL
Intervention: Cultured mucosal grafts
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional split-thickness palatal graft
Number of subjects: 8
Study: 2378424

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 319408

Group type: EXPERIMENTAL
Intervention: Beclamid (3-6 tablets a day according to weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Beclamid for 4 weeks followed by placebo for 4 weeks
Number of subjects: 60
Study: 30973261

Group type: EXPERIMENTAL
Intervention: Messenger delivering bad news (innocent messenger)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Desire to sense-make activated
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Unexpected bad news
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Awareness of messenger's benevolence
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Messenger motives manipulated independently from news valence
Number of subjects: 11
Study: 28870790

Group type: EXPERIMENTAL
Intervention: Intensity modulated WART
Number of subjects: 20
Study: 25592171

Group type: EXPERIMENTAL
Intervention: Weight-based estimation (insertion depth (cm) = weight (kg) + 6)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gestation-based estimation (value determined from a table)
Number of subjects: 90
Study: 23939537

Group type: EXPERIMENTAL
Intervention: Zolpidem sublingual tablet (ZST) 3.5 mg in fed state
Number of subjects: 100

Group type: COMPARATOR
Intervention: Zolpidem sublingual tablet (ZST) 3.5 mg in fasting state
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Zolpidem sublingual tablet (ZST) in fed state
Number of subjects: 100

Group type: COMPARATOR
Intervention: Zolpidem sublingual tablet (ZST) in fasting state
Number of subjects: 100
Study: 21878080

Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor) administered early (first 7 days) after myocardial revascularization
Number of subjects: 0
Study: 18782333

Group type: EXPERIMENTAL
Intervention: Comprehensive semiannual dental care
Number of subjects: 534
Study: 17298873

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention
Number of subjects: 281

Group type: COMPARATOR
Intervention: No-intervention (control)
Number of subjects: 281
Study: 15172773

Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 2463

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 2463
Study: 11325573

Group type: EXPERIMENTAL
Intervention: 15D
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 397

Group type: COMPARATOR
Intervention: EQ-5D and 15D
Number of subjects: 397
Study: 9394077

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms t.d.s.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms t.d.s.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (2 puffs t.d.s.)
Number of subjects: 12
Study: 8529851

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 1091

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 1091
Study: 2371597

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU) continuous regimen (5% cream applied nightly for 6 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil (5-FU) periodic regimen (5% cream applied 2 consecutive nights per week for 10 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Topical 5-fluorouracil (5-FU)
Number of subjects: 49
Study: 345887

Group type: EXPERIMENTAL
Intervention: Sustained release ephedrine-theophylline-phenobarbital (ETP) tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Terbutaline tablets
Number of subjects: 20
Study: 30204557

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 7
Study: 28841649

Group type: EXPERIMENTAL
Intervention: Combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose prednisolone (FIN-RACo DMARD combination)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Infliximab added on to the FIN-RACo DMARD combination
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo added on to the FIN-RACo DMARD combination
Number of subjects: 99
Study: 24235105

Group type: EXPERIMENTAL
Intervention: recombinant GH (rhGH; n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Plc; n = 6)
Number of subjects: 12
Study: 21743344

Group type: EXPERIMENTAL
Intervention: Nurse-initiated preoperative education and counseling
Number of subjects: 40
Study: 21246853

Group type: EXPERIMENTAL
Intervention: Mild moxibustion for 10 minutes on each point, once every other day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild moxibustion for 5 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild moxibustion once every day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild moxibustion for 12 weeks
Number of subjects: 0
Study: 18957613

Group type: EXPERIMENTAL
Intervention: CCK-8 at 0.33 ng.kg(‐1).min(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCK-8 at 0.66 ng.kg(‐1).min(‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCK-8 at 2.0 ng.kg(‐1).min(‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 15689903

Group type: EXPERIMENTAL
Intervention: Nanoduct conductivity measuring sweat test system
Number of subjects: 111

Group type: COMPARATOR
Intervention: Macroduct sweat collection system measuring chloride concentration
Number of subjects: 111
Study: 12515749

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (dietary therapy alone)
Number of subjects: 72
Study: 9890856

Group type: EXPERIMENTAL
Intervention: Chelation therapy for 2 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 32
Study: 7783051

Group type: EXPERIMENTAL
Intervention: Activated gelatinase-B present in synovial fluids (SF)
Number of subjects: 138

Group type: COMPARATOR
Intervention: No activated gelatinase-B in synovial fluids (SF)
Number of subjects: 138
Study: 2296877

Group type: EXPERIMENTAL
Intervention: Full dose of oral anticoagulants (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aspirin, 650 mg/day (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antithrombotic therapy (Group C)
Number of subjects: 60
Study: 6971092

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg intravenous every 4 hours for 48 hours, followed by 1 g oral daily for 10 days)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 31744452

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (TXA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 40
Study: 30847561

Group type: EXPERIMENTAL
Intervention: Inositol 2 g plus 200 µg of folic acid (twice daily for 3 months)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily plus 200 µg of folic acid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Letrozole 7.5 mg per day for 5 days (with folic acid)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (200 µg of folic acid as placebo)
Number of subjects: 150
Study: 28492910

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Aflibercept (2.0 mg)
Number of subjects: 362
Study: 25574796

Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 d·wk(‐1) at 400 kcal per session
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 d·wk(‐1) at 600 kcal per session
Number of subjects: 141

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 141
Study: 23338657

Group type: EXPERIMENTAL
Intervention: Propiverine extended-release (ER) 45 mg s.i.d.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Propiverine immediate-release (IR) 15 mg t.i.d.
Number of subjects: 66
Study: 21338987

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 20μg/drospirenone 3mg
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 19728607

Group type: EXPERIMENTAL
Intervention: Minimally invasive open reduction and internal fixation with improved compressing plate and screw
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard AO plate via L-shaped incision
Number of subjects: 64
Study: 17503974

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10, 15, 20, or 30 mg/day
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1187
Study: 15508561

Group type: EXPERIMENTAL
Intervention: Focused reflection and articulation instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no focused reflection and articulation instruction)
Number of subjects: 0
Study: 11816864

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10406689

Group type: EXPERIMENTAL
Intervention: Heparin-coated stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-coated stents
Number of subjects: 0
Study: 7524460

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2 x 10(6) KIU in the pump prime solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 40
Study: 3066983

Group type: EXPERIMENTAL
Intervention: Bemithyl (actoprotective agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 29318985

Group type: EXPERIMENTAL
Intervention: Cell salvage
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Routine care without salvage
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Cell salvage (emergency caesareans)
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Routine care without salvage (emergency caesareans)
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Cell salvage (elective caesareans)
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Routine care without salvage (elective caesareans)
Number of subjects: 3028
Study: 26586649

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24094768

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg intravenously once every 2 weeks
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 355
Study: 22937831

Group type: EXPERIMENTAL
Intervention: S. boulardii 250 mg once a day
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no S. boulardii supplementation)
Number of subjects: 179
Study: 20887413

Group type: EXPERIMENTAL
Intervention: Increased tidal volume (IV(T)) achieved by increasing the inspired plateau pressure 0.04 cmH(2)O/kg above the initial plateau pressure.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal tidal volume (NV(T)).
Number of subjects: 20
Study: 18179503

Group type: EXPERIMENTAL
Intervention: Geriatric home hospitalization service (GHHS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: General medical ward (GMW)
Number of subjects: 104
Study: 17409822

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1100 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 8) every 28 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m on days 1 and 8) plus Carboplatin (AUC = 5 on day 1) every 21 days
Number of subjects: 100
Study: 12862346

Group type: EXPERIMENTAL
Intervention: Cognitive Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (CAT/CLAMS)
Number of subjects: 0
Study: 11099372

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr; 5g, 4x/d for 4 days)
Number of subjects: 24
Study: 8736419

Group type: EXPERIMENTAL
Intervention: Orofacial physiotherapeutic treatment (OPT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 1558439

Group type: EXPERIMENTAL
Intervention: Tape seal applied to the catheter-drainage tubing junction
Number of subjects: 1740

Group type: COMPARATOR
Intervention: No tape seal (control group)
Number of subjects: 1740